Non-opioid Pain Treatment Market Size to Grow US$ 79.7 Billion By 2032

The global non-opioid pain treatment market size was approximate at US$ 42.3 billion in 2022 and is anticipated to grow US$ 79.7 billion by 2032, registering a compound annual growth rate of 6.54% from 2023 to 2032.

The non-opioid pain treatment market report covering various industry elements and growth trends helpful for predicting the market’s future.

The study provides a strong base for the non-opioid pain treatment market to be segmented into different segments. In fact, the study also covers the maximum market share during the assessment period by 2032.

This study is based on the partners that are highly competitive, key players as well as their market revenue in the forecast years of 2023 g0066ztr to 2032. There is also a strong focus on product revenues, sales, product categories and even the products that are experiencing the most traction. In this manner, the non-opioid pain treatment report also speaks about the effectiveness of this market along with its growth during the forecast period of 2030. Other major attributes of the non-opioid pain treatment market have been studied and analysed across many developments.

Request a Sample Copy of This Report @ https://www.precedenceresearch.com/sample/2616

Non-opioid Pain Treatment Market Report Scope 

Also read: Submarine Cable System Market Size to Grow US$ 41.02 Billion By 2032

Research Approach

The comprehensive report on the global non-opioid pain treatment market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products. Following this, the report provides detailed explanation of objectives of this study and laid down by accredited agencies in the purview of research in the global non-opioid pain treatment market.

It is followed by market introduction, market dynamics, and an overview of the global market, which includes analysis of market drivers, restraints, and trends pertaining to the global market. Furthermore, Y-o-Y growth analysis with elaborated insights has been provided in order to understand the Y-o-Y growth trend of the global market.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller sections. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

Key Players

• Novartis AG
• Teva Pharmaceutical Industries Limited
• Dr. Reddy’s Laboratories Ltd
• Sun Pharmaceutical Industries Ltd
• GSK plc.
• Pfizer Inc.
• Perrigo Company plc,
• LNK International, Inc.
• Cipla Inc.
• Johnson & Johnson Services, Inc.
• Pacira Pharmaceuticals, Inc.
• Pierrel

Non-opioid Pain Treatment Market Segmentations

By Drug Class

• NSAIDs
  • Selective COX-2 Inhibitors
  • Non-Selective NSAIDs
• Acetaminophen
• Local Anesthetics
• Others

By Pain Type

• Chronic Pain
  • Neuropathic Pain
  • Inflammatory Conditions
• Post-operative Pain
• Cancer Pain
• Others

By Route of Administration

• Oral
• Topical
• Injectable
• Others

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Others

By Geography

• North America
• Europe
• Asia-Pacific
• Latin America
• The Middle East and Africa

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Non-opioid Pain Treatment Market 

5.1. COVID-19 Landscape: Non-opioid Pain Treatment Industry Impact

5.2. COVID 19 – Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Non-opioid Pain Treatment Market, By Drug Class

8.1. Non-opioid Pain Treatment Market, by Drug Class, 2023-2032

8.1.1. NSAIDs

8.1.1.1. Market Revenue and Forecast (2020-2032)

8.1.2. Acetaminophen

8.1.2.1. Market Revenue and Forecast (2020-2032)

8.1.3. Local Anesthetics

8.1.3.1. Market Revenue and Forecast (2020-2032)

8.1.4. Others

8.1.4.1. Market Revenue and Forecast (2020-2032)

Chapter 9. Global Non-opioid Pain Treatment Market, By Pain Type

9.1. Non-opioid Pain Treatment Market, by Pain Type, 2023-2032

9.1.1. Chronic Pain

9.1.1.1. Market Revenue and Forecast (2020-2032)

9.1.2. Post-operative Pain

9.1.2.1. Market Revenue and Forecast (2020-2032)

9.1.3. Cancer Pain

9.1.3.1. Market Revenue and Forecast (2020-2032)

9.1.4. Others

9.1.4.1. Market Revenue and Forecast (2020-2032)

Chapter 10. Global Non-opioid Pain Treatment Market, By Route of Administration 

10.1. Non-opioid Pain Treatment Market, by Route of Administration, 2023-2032

10.1.1. Oral

10.1.1.1. Market Revenue and Forecast (2020-2032)

10.1.2. Topical

10.1.2.1. Market Revenue and Forecast (2020-2032)

10.1.3. Injectable

10.1.3.1. Market Revenue and Forecast (2020-2032)

10.1.4. Others

10.1.4.1. Market Revenue and Forecast (2020-2032)

Chapter 11. Global Non-opioid Pain Treatment Market, By Distribution Channel 

11.1. Non-opioid Pain Treatment Market, by Distribution Channel, 2023-2032

11.1.1. Hospital Pharmacy

11.1.1.1. Market Revenue and Forecast (2020-2032)

11.1.2. Retail Pharmacy

11.1.2.1. Market Revenue and Forecast (2020-2032)

11.1.3. Others

11.1.3.1. Market Revenue and Forecast (2020-2032)

Chapter 12. Global Non-opioid Pain Treatment Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Forecast, by Drug Class (2020-2032)

12.1.2. Market Revenue and Forecast, by Pain Type (2020-2032)

12.1.3. Market Revenue and Forecast, by Route of Administration (2020-2032)

12.1.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)

12.1.5. U.S.

12.1.5.1. Market Revenue and Forecast, by Drug Class (2020-2032)

12.1.5.2. Market Revenue and Forecast, by Pain Type (2020-2032)

12.1.5.3. Market Revenue and Forecast, by Route of Administration (2020-2032)

12.1.5.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Forecast, by Drug Class (2020-2032)

12.1.6.2. Market Revenue and Forecast, by Pain Type (2020-2032)

12.1.6.3. Market Revenue and Forecast, by Route of Administration (2020-2032)

12.1.6.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)

12.2. Europe

12.2.1. Market Revenue and Forecast, by Drug Class (2020-2032)

12.2.2. Market Revenue and Forecast, by Pain Type (2020-2032)

12.2.3. Market Revenue and Forecast, by Route of Administration (2020-2032)

12.2.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)

12.2.5. UK

12.2.5.1. Market Revenue and Forecast, by Drug Class (2020-2032)

12.2.5.2. Market Revenue and Forecast, by Pain Type (2020-2032)

12.2.5.3. Market Revenue and Forecast, by Route of Administration (2020-2032)

12.2.5.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)

12.2.6. Germany

12.2.6.1. Market Revenue and Forecast, by Drug Class (2020-2032)

12.2.6.2. Market Revenue and Forecast, by Pain Type (2020-2032)

12.2.6.3. Market Revenue and Forecast, by Route of Administration (2020-2032)

12.2.6.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)

12.2.7. France

12.2.7.1. Market Revenue and Forecast, by Drug Class (2020-2032)

12.2.7.2. Market Revenue and Forecast, by Pain Type (2020-2032)

12.2.7.3. Market Revenue and Forecast, by Route of Administration (2020-2032)

12.2.7.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Forecast, by Drug Class (2020-2032)

12.2.8.2. Market Revenue and Forecast, by Pain Type (2020-2032)

12.2.8.3. Market Revenue and Forecast, by Route of Administration (2020-2032)

12.2.8.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)

12.3. APAC

12.3.1. Market Revenue and Forecast, by Drug Class (2020-2032)

12.3.2. Market Revenue and Forecast, by Pain Type (2020-2032)

12.3.3. Market Revenue and Forecast, by Route of Administration (2020-2032)

12.3.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)

12.3.5. India

12.3.5.1. Market Revenue and Forecast, by Drug Class (2020-2032)

12.3.5.2. Market Revenue and Forecast, by Pain Type (2020-2032)

12.3.5.3. Market Revenue and Forecast, by Route of Administration (2020-2032)

12.3.5.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)

12.3.6. China

12.3.6.1. Market Revenue and Forecast, by Drug Class (2020-2032)

12.3.6.2. Market Revenue and Forecast, by Pain Type (2020-2032)

12.3.6.3. Market Revenue and Forecast, by Route of Administration (2020-2032)

12.3.6.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)

12.3.7. Japan

12.3.7.1. Market Revenue and Forecast, by Drug Class (2020-2032)

12.3.7.2. Market Revenue and Forecast, by Pain Type (2020-2032)

12.3.7.3. Market Revenue and Forecast, by Route of Administration (2020-2032)

12.3.7.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Forecast, by Drug Class (2020-2032)

12.3.8.2. Market Revenue and Forecast, by Pain Type (2020-2032)

12.3.8.3. Market Revenue and Forecast, by Route of Administration (2020-2032)

12.3.8.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)

12.4. MEA

12.4.1. Market Revenue and Forecast, by Drug Class (2020-2032)

12.4.2. Market Revenue and Forecast, by Pain Type (2020-2032)

12.4.3. Market Revenue and Forecast, by Route of Administration (2020-2032)

12.4.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)

12.4.5. GCC

12.4.5.1. Market Revenue and Forecast, by Drug Class (2020-2032)

12.4.5.2. Market Revenue and Forecast, by Pain Type (2020-2032)

12.4.5.3. Market Revenue and Forecast, by Route of Administration (2020-2032)

12.4.5.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)

12.4.6. North Africa

12.4.6.1. Market Revenue and Forecast, by Drug Class (2020-2032)

12.4.6.2. Market Revenue and Forecast, by Pain Type (2020-2032)

12.4.6.3. Market Revenue and Forecast, by Route of Administration (2020-2032)

12.4.6.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)

12.4.7. South Africa

12.4.7.1. Market Revenue and Forecast, by Drug Class (2020-2032)

12.4.7.2. Market Revenue and Forecast, by Pain Type (2020-2032)

12.4.7.3. Market Revenue and Forecast, by Route of Administration (2020-2032)

12.4.7.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Forecast, by Drug Class (2020-2032)

12.4.8.2. Market Revenue and Forecast, by Pain Type (2020-2032)

12.4.8.3. Market Revenue and Forecast, by Route of Administration (2020-2032)

12.4.8.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)

12.5. Latin America

12.5.1. Market Revenue and Forecast, by Drug Class (2020-2032)

12.5.2. Market Revenue and Forecast, by Pain Type (2020-2032)

12.5.3. Market Revenue and Forecast, by Route of Administration (2020-2032)

12.5.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)

12.5.5. Brazil

12.5.5.1. Market Revenue and Forecast, by Drug Class (2020-2032)

12.5.5.2. Market Revenue and Forecast, by Pain Type (2020-2032)

12.5.5.3. Market Revenue and Forecast, by Route of Administration (2020-2032)

12.5.5.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Forecast, by Drug Class (2020-2032)

12.5.6.2. Market Revenue and Forecast, by Pain Type (2020-2032)

12.5.6.3. Market Revenue and Forecast, by Route of Administration (2020-2032)

12.5.6.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)

Chapter 13. Company Profiles

13.1. Novartis AG

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. Teva Pharmaceutical Industries Limited

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. Dr. Reddy’s Laboratories Ltd

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. Sun Pharmaceutical Industries Ltd

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. GSK plc.

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. Pfizer Inc.

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. Perrigo Company plc,

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. LNK International, Inc.

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. Cipla Inc.

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

13.10. Johnson & Johnson Services, Inc.

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial Performance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms

Why should you invest in this report?

If you are aiming to enter the global non-opioid pain treatment market, this report is a comprehensive guide that provides crystal clear insights into this niche market. All the major application areas for non-opioid pain treatment are covered in this report and information is given on the important regions of the world where this market is likely to boom during the forecast period of 2023-2030 so that you can plan your strategies to enter this market accordingly.

Besides, through this report, you can have a complete grasp of the level of competition you will be facing in this hugely competitive market and if you are an established player in this market already, this report will help you gauge the strategies that your competitors have adopted to stay as market leaders in this market. For new entrants to this market, the voluminous data provided in this report is invaluable.

Contact Us:

Mr. Alex

Sales Manager

Call: +1 9197 992 333

Email: sales@precedenceresearch.com

Web: https://www.precedenceresearch.com

Blog: https://www.pharma-geek.com